A phase II study of weekly paclitaxel in platinum and paclitaxel-resistant ovarian cancer patients.

@article{Kaern2002API,
  title={A phase II study of weekly paclitaxel in platinum and paclitaxel-resistant ovarian cancer patients.},
  author={Janne Kaern and Mark M O Baekelandt and Claes G{\"o}ran Trop{\'e}},
  journal={European journal of gynaecological oncology},
  year={2002},
  volume={23 5},
  pages={383-9}
}
OBJECTIVE In platinum-resistant ovarian cancer weekly paclitaxel has shown an equal efficiency and better toxicity profile compared to three-weekly paclitaxel in platinum-resistant ovarian cancer. We wanted to study response rate, response duration and toxicity in platinum-resistant tumors with emphasis on tumors also resistant to three-weekly paclitaxel. MATERIAL AND METHODS Fifty-seven patients with platinum-resistant disease, treated with weekly paclitaxel 80 mg/m2, 1-hour infusion, were… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 13 extracted citations

Dose-dense paclitaxel in advanced ovarian cancer.

Clinical oncology (Royal College of Radiologists (Great Britain)) • 2015

Clinical trials and progress with paclitaxel in ovarian cancer

International journal of women's health • 2010
View 1 Excerpt

Similar Papers

Loading similar papers…